Aneurysm characteristics, treatment complications, and morbidity and mortality in patients treated with WEB DL and WEB SL (and SLS)

WEB DLWEB SL/SLSP Value
Patients3032
    Age (mean) (yr)55.6 ± 8.957.4 ± 10.3.86
    Female24/30 (80.0%)16/32 (50.0%).20
Aneurysms3132
    Ruptured2/31 (6.5%)5/32 (15.6%).42
    AcomA4/31 (12.9%)12/32 (37.5%).04
    Aneurysm <10 mm21/31 (67.7%)31/32 (96.9%).002
    Neck >4 mm29/31 (96.5%)28/32 (87.5%).67
Antiplatelet treatmenta
    Before treatment4/30 (13.3%)11/32 (34.4%).07
    During treatment22/30 (73.3%)20/32 (62.5%).42
    After treatment26/30 (86.7%)22/32 (68.8%).13
Treatment feasibility30/31 (96.8%)32/32 (100.0%).49
Adjunctive treatment4/30 (13.3%)3/32 (9.4%).70
Adverse events
    Device problems3/30 (10.0%)2/32 (6.3%).66
    TEb7/30 (23.3%)3/32 (9.4%).17
    IOR1/30 (3.3%)0/32 (0.0%).48
Morbidity/mortality
    Morbidity1/30 (3.3%)1/32 (3.1%)1
    Mortality0/30 (0.0%)0/32 (0.0%)1

  • Note:—TE indicates thromboembolic event/appearance of thrombus; IOR, intraoperative rupture.

  • ↵a One or 2 medications.

  • ↵b DL group: no clinical deficit in 3, transient deficits in 3, permanent deficit in 1. SL group: no deficit in 1, transient deficits in 2.